Adjuvanted inactivated influenza A(H3N2) vaccines induce stronger immunogenicity in mice and confer higher protection in ferrets than unadjuvanted inactivated vaccines

Vaccine

Volumn 32, Issue 43, 2014, Pages 5730-5739

  Ann, Julie ^a   Samant, Mukesh ^a   Rheaume, Chantal ^a   Dumas, Carole ^a   Beaulieu, Edith ^b   Morasse, Audrey ^b   Mallett, Corey ^b   Hamelin, Marie Eve ^a   Papadopoulou, Barbara ^a   Boivin, Guy ^a  

^a Université Laval   (Canada)

^b GLAXOSMITHKLINE   (Canada)

Author keywords

Adjuvants; Ferrets; H3N2 vaccine; Influenza; Mice

Indexed keywords

ALPHA TOCOPHEROL; GAMMA INTERFERON; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; INACTIVATED VACCINE; INFLUENZA VACCINE; INTERLEUKIN 2; INTERLEUKIN 4; PHOSPHORYL LIPID A; SPLIT INACTIVATED INFLUENZA VACCINE; SQUALENE; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG; CYSTEINE PROTEINASE; CYTOKINE; DRUG COMBINATION; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; LIPOPOLYSACCHARIDE; PROTOLLIN; VIRUS ANTIBODY;

ADJUVANT THERAPY; ANTIBODY RESPONSE; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL EVALUATION; CONTROLLED STUDY; CROSS PROTECTION; CYTOKINE PRODUCTION; FEMALE; FERRET; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; IN VITRO STUDY; LUNG LAVAGE; MALE; MOUSE; NONHUMAN; TEMPERATURE; TREATMENT DURATION; VACCINATION; WEIGHT REDUCTION; ANIMAL; BAGG ALBINO MOUSE; BLOOD; DRUG COMBINATION; IMMUNOLOGY; INFLUENZA VIRUS A H3N2; MUCOSAL IMMUNITY; ORTHOMYXOVIRIDAE INFECTIONS; TH1 CELL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, VIRAL; CROSS PROTECTION; CYSTEINE ENDOPEPTIDASES; CYTOKINES; DRUG COMBINATIONS; FEMALE; FERRETS; IMMUNITY, HUMORAL; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN G; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA VACCINES; LIPOPOLYSACCHARIDES; MALE; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS; TH1 CELLS; VACCINES, INACTIVATED;

EID: 84908461062     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.08.029     Document Type: Article

References (30)

1. Fields B.N., Knipe D.M., Howley P.M. Fields virology 2013, 1151. Wolters Kluwer Health/Lippincott Williams & Wilkins, Philadelphia.
2. Lambert L.C., Fauci A.S. Influenza vaccines for the future. N Engl J Med 2010, 363(21 Nov):2036-2044.
3. Mastelic B., Ahmed S., Egan W.M., Del Giudice G., Golding H., Gust I., et al. Mode of action of adjuvants: implications for vaccine safety and design. Biologicals 2010, 38(5 Sep):594-601.
4. Rumke H.C., Richardus J.H., Rombo L., Pauksens K., Plassmann G., Durand C., et al. Selection of an adjuvant for seasonal influenza vaccine in elderly people: modelling immunogenicity from a randomized trial. BMC Infect Dis 2013, 13:348.
5. Baras B., Stittelaar K.J., Simon J.H., Thoolen R.J., Mossman S.P., Pistoor F.H., et al. Cross-protection against lethal H5N1 challenge in ferrets with an adjuvanted pandemic influenza vaccine. PloS One 2008, 3(1):e1401.
6. Chu D.W., Hwang S.J., Lim F.S., Oh H.M., Thongcharoen P., Yang P.C., et al. Immunogenicity and tolerability of an AS03(A)-adjuvanted prepandemic influenza vaccine: a phase III study in a large population of Asian adults. Vaccine 2009, 27(52 Dec):7428-7435.
7. McElhaney J.E., Beran J., Devaster J.M., Esen M., Launay O., Leroux-Roels G., et al. AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trial. Lancet Infect Dis 2013, 13(6 Jun):485-496.
8. Guy B. The perfect mix: recent progress in adjuvant research. Nat Rev 2007, 5(7 Jul):505-517.
9. Jones T., Cyr S., Allard F., Bellerose N., Lowell G.H., Burt D.S. Protollin: a novel adjuvant for intranasal vaccines. Vaccine 2004, 22(27-28 Sep):3691-3697.
10. Baz M., Samant M., Zekki H., Tribout-Jover P., Plante M., Lanteigne A.M., et al. Effects of different adjuvants in the context of intramuscular and intranasal routes on humoral and cellular immune responses induced by detergent-split A/H3N2 influenza vaccines in mice. Clin Vaccine Immunol 2012, 19(2 Feb):209-218.
11. Morel S., Didierlaurent A., Bourguignon P., Delhaye S., Baras B., Jacob V., et al. Adjuvant System AS03 containing alpha-tocopherol modulates innate immune response and leads to improved adaptive immunity. Vaccine 2011, 29(13 Mar):2461-2473.
12. WHO Manual on Animal Influenza Diagnosis and Surveillance; 2002 [cited 2011, 11 May]. Available from: (). http://www.who.int/vaccine_research/diseases/influenza/WHO_manual_on_animal-diagnosis_and_surveillance:2002_5.pdf.
13. Brunner R., Jensen-Jarolim E., Pali-Scholl I. The ABC of clinical and experimental adjuvants-a brief overview. Immunol Lett 2010, 128(1 Jan):29-35.
14. Garcon N. Preclinical development of AS04. Methods in molecular biology (Clifton, NJ 2010;626:15-27).
15. Fransen F., Boog C.J., van Putten J.P., van der Ley P. Agonists of Toll-like receptors 3, 4, 7, and 9 are candidates for use as adjuvants in an outer membrane vaccine against Neisseria meningitidis serogroup B. Infect Immun 2007, 75(12 Dec):5939-5946.
16. Casella C.R., Mitchell T.C. Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant. Cell Mol Life Sci 2008, 65(20 Oct):3231-3240.
17. Duthie M.S., Windish H.P., Fox C.B., Reed S.G. Use of defined TLR ligands as adjuvants within human vaccines. Immunol Rev 2011, 239(1 Jan):178-196.
18. Phillipps K.S., Wykes M.N., Liu X.Q., Brown M., Blanchfield J., Toth I. A novel synthetic adjuvant enhances dendritic cell function. Immunology 2009, 128(1 Suppl Sep):e582-e588.
19. Holvast B., Huckriede A., Kallenberg C.G., Bijl M. Influenza vaccination in systemic lupus erythematosus: safe and protective?. Autoimmun Rev 2007, 6(5 Apr):300-305.
20. Chabot S., Brewer A., Lowell G., Plante M., Cyr S., Burt D.S., et al. A novel intranasal Protollin-based measles vaccine induces mucosal and systemic neutralizing antibody responses and cell-mediated immunity in mice. Vaccine 2005, 23(11 Feb):1374-1383.
21. Cyr S.L., Angers I., Guillot L., Stoica-Popescu I., Lussier M., Qureshi S., et al. TLR4 and MyD88 control protection and pulmonary granulocytic recruitment in a murine intranasal RSV immunization and challenge model. Vaccine 2009, 27(3 Jan):421-430.
22. Magnusson S.E., Reimer J.M., Karlsson K.H., Lilja L., Bengtsson K.L., Stertman L. Immune enhancing properties of the novel Matrix-M adjuvant leads to potentiated immune responses to an influenza vaccine in mice. Vaccine 2013, 31(13 Mar):1725-1733.
23. Roman F., Clement F., Dewe W., Walravens K., Maes C., Willekens J., et al. Effect on cellular and humoral immune responses of the AS03 adjuvant system in an A/H1N1/2009 influenza virus vaccine administered to adults during two randomized controlled trials. Clin Vaccine Immunol 2011, 18(5 May):835-843.
24. van Riet E., Ainai A., Suzuki T., Hasegawa H. Mucosal IgA responses in influenza virus infections; thoughts for vaccine design. Vaccine 2012, 30(40 Aug):5893-5900.
25. Langley J.M., Aoki F., Ward B.J., McGeer A., Angel J.B., Stiver G., et al. A nasally administered trivalent inactivated influenza vaccine is well tolerated, stimulates both mucosal and systemic immunity, and potentially protects against influenza illness. Vaccine 2011, 29(10 Feb):1921-1928.
26. O'Hagan D.T., Rappuoli R. Novel approaches to vaccine delivery. Pharm Res 2004, 21(9 Sep):1519-1530.
27. Glenn G.M., Kenney R.T. Mass vaccination: solutions in the skin. Curr Top Microbiol Immunol 2006, 304:247-268.
28. Prausnitz M.R., Mikszta J.A., Cormier M., Andrianov A.K. Microneedle-based vaccines. Curr Top Microbiol Immunol 2009, 333:369-393.
29. Belser J.A., Katz J.M., Tumpey T.M. The ferret as a model organism to study influenza A virus infection. Dis Models Mech 2011, 4(5 Sep):575-579.
30. Belser J.A., Szretter K.J., Katz J.M., Tumpey T.M. Use of animal models to understand the pandemic potential of highly pathogenic avian influenza viruses. Adv Virus Res 2009, 73:55-97.